A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

Summary

This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.

Timeline

Start

2026-01

Primary completion

2028-02

Completion

2028-02

Drugs

Indications